Primary outcomes
SE, sleep behavior disorder, PD, RBD
Groups were statistically equivalent on the primary measure at baseline. Linear mixed models estimated a statistically significant reduction of RBD in the SXB group of 23.1 episodes per month (SE = 6.4, 95% CI −36.0, −10.2, Summary of Parameter Estimates from ITT Linear Mixed Models of Number of RBD Episodes Over Time (Baseline, Titration, Final Dose)CI, confidence interval; ITT, intention-to-treat; RBD, rapid-eye-movement sleep behavior disorder; SXB, sodium oxybateResults were similar when within- and between-group changes were analyzed using more conservative nonparametric tests (Efficacy Measures of RBD Activity Per RBD Logs and Video-PolysomnographyIQR, interquartile range; PSG, polysomnography.






There was no correlation between the reduction in number of RBD episodes and age, gender, or PD status.